Colonial River Investments LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 5,997 shares of the company's stock, valued at approximately $333,000.
Several other large investors also recently made changes to their positions in the company. Lee Danner & Bass Inc. bought a new position in Sanofi in the fourth quarter worth approximately $31,000. Bessemer Group Inc. raised its position in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. UMB Bank n.a. grew its position in Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the period. Finally, Tsfg LLC increased its stake in Sanofi by 1,107.0% during the 1st quarter. Tsfg LLC now owns 1,207 shares of the company's stock valued at $67,000 after purchasing an additional 1,107 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Price Performance
Sanofi stock opened at $47.85 on Friday. The stock has a market cap of $117.35 billion, a P/E ratio of 17.09, a P/E/G ratio of 0.99 and a beta of 0.50. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The company's 50 day moving average price is $50.95 and its two-hundred day moving average price is $52.02. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the previous year, the firm earned $1.78 earnings per share. The business's revenue was down 11.0% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is 57.14%.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on SNY. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $61.50.
Check Out Our Latest Stock Analysis on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
